TIGIT and neoplasm: Furthermore, the blockade of the checkpoint receptor, TIGIT, promotes NK cell-based tumor-specific T cell immunity, further highlighting the contribution of NK cells to the restoration of tumor-specific CD8+ T cell immune responses (145).